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Abstract: Background: Drug-induced interstitial lung disease (DIILD) occurs as a result of numerous
agents, but the risk often only becomes apparent after the marketing authorisation of such agents.
Methods: In this PRISMA-compliant systematic review, we aimed to evaluate and synthesise the
current literature on DIILD. Results: Following a quality assessment, 156 full-text papers describing
more than 6000 DIILD cases were included in the review. However, the majority of the papers were
of low or very low quality in relation to the review question (78%). Thus, it was not possible to
perform a meta-analysis, and descriptive review was undertaken instead. DIILD incidence rates
varied between 4.1 and 12.4 cases/million/year. DIILD accounted for 3–5% of prevalent ILD cases.
Cancer drugs, followed by rheumatology drugs, amiodarone and antibiotics, were the most common
causes of DIILD. The radiopathological phenotype of DIILD varied between and within agents,
and no typical radiological pattern specific to DIILD was identified. Mortality rates of over 50%
were reported in some studies. Severity at presentation was the most reliable predictor of mortality.
J. Clin. Med. 2018, 7, 356; doi:10.3390/jcm7100356 www.mdpi.com/journal/jcm
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Glucocorticoids (GCs) were commonly used to treat DIILD, but no prospective studies examined
their effect on outcome. Conclusions: Overall high-quality evidence in DIILD is lacking, and the
current review will inform larger prospective studies to investigate the diagnosis and management
of DIILD.
Keywords: drug-induced interstitial lung disease; pulmonary toxicity; drug-induced pneumonitis
1. Introduction
Drug-induced interstitial lung disease (DIILD) occurs when exposure to a drug causes
inflammation and eventually fibrosis of the lung interstitium. Over 350 drugs may cause DIILD,
but liability is often not recognised until late in drug development, or after launch. New causative
drugs are regularly identified, with over 1300 drugs, procedures or substances reported to cause
respiratory problems on the comprehensive Pneumotox website (www.pneumotox.com). DIILD
is a recognised subtype of diffuse parenchymal lung diseases according to the American Thoracic
Society/European Respiratory Society (ATS/ERS) classification [1], but clinical, pathological and
radiological features are rarely specific and difficult to distinguish from other interstitial pneumonias.
Moreover, the clinical phenotype, imaging and histopathology patterns vary significantly between
drugs and between patients on the same drug. DIILD is consequently a diagnosis of exclusion, and this
poses unique challenges for the treating physician and for the study of DIILD in both epidemiological
and drug development settings.
DIILD is diagnosed on the basis of clinical, physiological and radiological findings consistent
with ILD; a temporal relationship between onset of symptoms and drug exposure; absence of another
more likely cause, e.g., infection, pulmonary oedema, radiation-induced lung injury, progression of
the underlying disease; and improvement upon withdrawal of the suspected causative agent with or
without corticosteroid therapy and, in some cases, deterioration upon re-challenge. An internationally
agreed severity classification is used in clinical trials (Table 1) [2].
Table 1. Grading of drug-induced interstitial lung disease (DIILD) based on the National Cancer
Institute Common Terminology Criteria for Adverse Events [2].
Grade 1 (mild) Asymptomatic, radiographic findings only
Grade 2 (moderate) Symptomatic, not interfering with activities of daily living
Grade 3 (severe) Symptomatic, interfering with activities of daily living or oxygen indicated
Grade 4 (life-threatening or disabling) Life-threatening, or ventilator support required
Grade 5 (fatal)
Drugs and patterns of disease are catalogued in the International Database “Pneumotox” (www.
pneumotox.com). However, there is no detailed overall picture of the incidence, phenotype and
clinical course of DIILD. The Translational Imaging in Drug Safety Initiative (TRISTAN) consortium
is designing prospective studies to develop sensitive and specific biomarkers in patients with DIILD
(http://www.imi-tristan.eu). The aim of this systematic review is to summarise the current knowledge
of DIILD as a useful guide to clinicians and to inform the TRISTAN studies.
2. Methods
We conducted a systematic review of observational studies in accordance with the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses consensus guidelines (PRISMA) [3], with
the aims of: (1) determining the incidence and prevalence of DIILD, (2) identifying common causative
drugs, (3) identifying risk factors for DIILD, (4) comparing imaging and non-imaging investigations for
assessment and diagnosis of DIILD, (5) assessing the prevalence of DIILD subtypes, (6) measuring the
impact of glucocorticoid therapy on outcomes and (7) defining the prognosis of DIILD. We searched
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Medline, Embase and The Cochrane Register of Controlled Trials in May 2017 using theMedical Subject
Headings (MESH) and keyword searches detailed in Figure 1. The following exclusion criteria were
applied: studies not in English language, non-human studies, sample size of less than 10, DIILD related
to non-licensed drugs and chemicals, e.g., alcohol or organophosphates. Two authors independently
screened the titles and abstracts for eligibility. In circumstances where it was not clear from the
abstract that the study was eligible, the paper was included in the full-text review. Any disagreements
regarding abstract inclusion were resolved by a third independent reviewer. Additional papers were
also identified through grey (manual) searches. Full texts of eligible papers were obtained and assessed
for inclusion in duplicate, with two reviewers allocated to each question. In the case of overlap
between articles reporting the same cohort, we included the study with the largest cohort. The quality
of evidence and risk of bias were assessed using the Grading Recommendations Assessment and
Development Evidence (GRADE) criteria with supporting guidance from the Cochrane website [4].
Data were extracted using the Population, Intervention, Comparison, Outcome (PICO) framework and
included title, year of publication, study design, sample size, study population, patient characteristics,
intervention and comparator (where applicable), outcomes, funding and conclusions. The study was
prospectively registered on the PROSPERO website (registration number: CRD42017071276). Data
were evaluated for inclusion in a meta-analysis based on quality and bias, and, if excluded, descriptive
synthesis was undertaken.
 
Figure 1. Search terms used in Medline, Embase and Cochrane Register of Controlled Trials.
3. Results
After de-duplication, we reviewed 1694 titles and abstracts; from these, we included 185 (10.9%)
in a full-text review (Figure 2). A further 66 articles were excluded after full review, and 37 were
included in grey searches, providing a total of 156 articles eligible for inclusion. The most common
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reasons for exclusion of full-text papers were that the study provided no information relevant to the
study questions (e.g., described all adverse drug events without specific information on DIILD) (n =
24), it took the form of a narrative review (n = 20) or the sample size was less than 10 (n = 12). Of those
where sample size was less than 10, only one drug was not described in the other included papers
(hydroxyurea). Potential biases and the quality of included articles are described in Figure 3. The
majority were low or very low quality (78%), and 90% had a high risk of bias, mainly due to significant
limitations in design, poor precision and indirectness of the study population. Another major limitation
was the lack of standardised case definition for DIILD; some studies used physician-reported diagnosis,
others used radiological evidence of ILD to define cases without an assessment of clinical characteristics
or exclusion of infection, and workup to exclude another competing diagnosis was not stated, minimal
or absent. In many studies, a significant proportion of subjects were asymptomatic. A number of
post-marketing studies attempted to address this with an expert panel case review and verification
process. However, the overall lack of standardised case definition and a paucity of independent case
verification hampered any quantitative data synthesis.
 
Figure 2. Flow diagram of the review process from abstract review to final inclusion. In total, these
156 articles report approximately 6200 patients with confirmed or suspected DIILD, which was fatal in
around 672/2647 (25.4%) cases.
We also noted a geographical bias, with more than one-third of the studies (mainly large
post-marketing registers) being reported from Japan. A higher prevalence of reported ILD compared to
the West has previously been noted in Japanese populations; however, much of this has been suggested
to be artefactual due to coding and spontaneous reporting practices, rather than biological reasons [5].
The Proportional Reporting Ratio method was not used [6].
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Due to the overall poor quality of evidence, meta-analyses for individual questions were not
possible, and a descriptive review was subsequently undertaken.
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
Risk of bias (%) 
Risk of bias (%) 
High  90.3 
Unclear 1.9 
Low 7.7 
A. Risk of bias 
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 
Quality (%) 
Quality (%) 
High 1.9 
Moderate 18.1 
Low 49 
Very low 29 
B. Study quality 
Figure 3. Summary of quality and bias, as assessed using the Grading Recommendations Assessment
and Development Evidence (GRADE) method [4]. (A) Summarises risk of bias and (B) summarises
quality of included studies.
3.1. Incidence and Prevalence
The reported incidence of DIILD for individual drugs ranged from <1% to almost 60% (Table 2).
Many studies relied on spontaneous physician or administrative reporting and are susceptible to
reporting bias for positive cases.
At a population level, a study from the Clinical Practice Research Database (UK) between 1997
and 2008 reported an incidence of 4.1 per million per annum [7] based on 128 patients with drug- (n =
22) or radiation-induced (n = 106) ILD. This is likely to be a significant underestimate, considering
the case definitions they used and the primary care nature of the cohort. Furthermore, since these
figures were published, there has been a significant expansion of new oncology drugs with a high rate
of DIILD (www.pneumotox.com). A more recent study in a county within Greater Paris estimated
the incidence of all ILD cases at 19.4 per 100,000 per year based on both primary and secondary care
data [8]. DIILD accounted for 6.4% of incident cases, suggesting a rate of 12.4 cases per million per year.
However, the authors acknowledged that the population was not representative of the demographic
structure of the French general population. A few studies also examined rates of DIILD within ILD
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populations [8–11]. Four ILD cohorts of 848, 237, 460 and 431 cases of ILD estimated the prevalence of
DIILD to be 3%, 3%, 2.6% and 5%, respectively [8–11].
3.2. Common Causative Drugs
We identified six single-centre studies that comprehensively reported DIILD rates for individual
drugs in unselected DIILD cohorts [12–17]. Not all studies reported DIILD as the primary objective:
five were retrospective studies and four were from a single region (Japan). Cancer drugs were the
leading cause of DIILD in most studies, accounting for 23–51% of cases, followed by disease-modifying
anti-rheumatic drugs (DMARDs) (6–72%), antibiotics (6–26%), non-steroidal anti-inflammatory agents
(NSAIDs) (0–23%), psychiatric medications (0–9%) and anti-arrhythmic agents (0–9%). In the Flanders
ILD registry, amiodarone followed by nitrofurantoin were the most common causes [10]. Table 1
summarises the incidence and mortality rates for DIILD studies relating to specific agents or drug
classes. Consistent with results from unselected DIILD cohort studies, cancer drugs accounted for
the majority of drug-specific published studies identified in the initial search (n = 37), followed by
DMARDs (n = 12), cardiology medications (n = 10) and antibiotics (n = 7).
3.2.1. Cancer Therapy
Identifying specific causative agents is challenging in oncology when drugs are given in
combination regimens, or in association with thoracic radiotherapy, which is independently associated
with lung fibrosis. The most common individual cancer drugs causing DIILD were identified as
bleomycin, gemcitabine, epidermal growth factor receptor (EGFR)-directed therapies, mechanistic
target of rapamycin protein (MTOR) inhibitors and immune checkpoint inhibitors. Methotrexate,
which is used for the treatment of cancer as well as rheumatological conditions, was also identified.
Bleomycin
Bleomycin, used predominantly to treat Hodgkin’s lymphoma and germ cell tumours, causes
lung injury via immune-mediated and direct toxic effects [18,19]. The reported risk is 6.8–21%, with an
associated mortality rate of up to 48% [18–23]. The clinical presentation of bleomycin lung injury is
highly variable but can be asymptomatic. Up to 39% of cases are detected on imaging alone [22,23].
Pulmonary physiology changes are common and include an early reduction in diffusing capacity of the
lung for carbon monoxide (DLCO) followed by changes in forced vital capacity (FVC), which correlates
with symptomatic deterioration [18,22].
DIILD can occur at any time during treatment [18]. A study in germ cell tumour patients
treated with high-dose bleomycin reported a median time from bleomycin initiation to DIILD of 4.2
months [23]. In this study, cumulative doses >300,000 international units were associated with a
3.5-fold increased risk of DIILD. Idiosyncratic reactions at low doses early in the treatment course are
also less commonly described [18,23]. Recent advances in positron emission tomography-directed
omission of bleomycin in selected patients with Hodgkin’s lymphoma have been associated with a
significant reduction in pulmonary toxicity [24].
Gemcitabine
Gemcitabine is used to treat a range of cancers, including non-small cell lung cancer (NSCLC),
pancreatic cancer and breast cancer [13,25–28]. The risk of DIILD is highest when used in combination
with other agents, especially bleomycin, erlotinib and taxanes [25,26,28–31], with reported incidence
rates of 1–20%. Mortality rates are generally low [26–28,32] except in severe cases requiring
hospitalisation, where mortality reaches 20% [30]. In contrast to bleomycin, the dose relationship and
timing of onset are less consistent [13,26,29].
A nationwide retrospective database study in Japan identified 428 cases of DIILD in 25,924
gemcitabine-treated patients [30]. The median time of onset was 65 days and the cumulative incidence
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was 1.1%, 1.5% and 1.9% at 3, 6 and 12 months. The crude incidence rates were similar after
monotherapy (1.7%) and combination therapy (1.6%).
Epidermal Growth Factor Receptor (EGFR)-Targeted Agents
EGFR-targeted agents include small molecule receptor tyrosine kinase inhibitors (RTKIs) and
monoclonal antibodies licenced for treatment of NSCLC, breast cancer and colorectal cancer [33,34].
The reported incidence of DIILD for the EGFR-RTKIs gefitinib and erlotinib is 1.2–1.6%, with an
associated mortality rate of 22.8% [35,36]. DIILD following EGFR-RTKIs appears to be an early event,
with studies of gefitinib and erlotinib reporting the highest incidence within 4 weeks of starting
treatment [34,37].
In Japanese post-marketing surveillance studies, the incidence of DIILD with EGFR-directed
monoclonal antibodies, such as panitumumab and cetuximab, was 1.3% and 1.2%, respectively, with a
broad time to onset (median 101 days, range 17–431) [33,38]. Another study reported a median onset
of 113 days (range 1–559) following the first dose of panitumumab, with 11/39 cases occurring after 6
months of therapy [39]. Notably, many patients in this series also received treatment in combination
with other agents associated with DIILD risk. A single study in Japan reported mortality rates of 41.6%
and 51.3% for cetuximab- and panitumumab-related DIILD, respectively [33].
Mechanistic Target of Rapamycin Protein (MTOR) Inhibitors
MTOR inhibitors are used predominantly to treat renal cell cancers and neuroendocrine tumours,
and as anti-rejection agents in solid organ transplantation [40–45]. Sirolimus, temsirolimus and
everolimus have all been associated with pulmonary toxicity [45–47]. A meta-analysis of 2233
everolimus-treated cancer patients in five clinical trials reported a DIILD incidence of 10.4% (all
grades) and 2.4% (grade 3–4). Mortality data were not reported, and no associations with treatment
duration, gender or cancer outcomes were observed [46]. Cases were observed in not only Japanese
centres but also Western countries.
Post hoc analysis of computerised tomography (CT) data from clinical trials of temsirolimus and
everolimus found a significantly higher incidence of radiographic changes consistent with DIILD
(everolimus radiographic 53.9% vs. clinical 13.5%; temsirolimus 29% vs. 6%) [42,45,47].
In organ transplant recipients, variable incidence rates ranging from 2.8% to 12.7% have been
reported in observational studies [41,48,49].
Immune Checkpoint Inhibitors
Checkpoint inhibitors of programmed cell death 1 (PD-1) and its ligands (PD-L1 and PD-L2) and
cytotoxic lymphocyte antigen protein 4 (CTLA-4) are an emerging class of agents currently licensed in
metastatic melanoma, NSCLC and Hodgkin’s lymphoma [50–52]. Immune-mediated reactions are
well recognised [50]. A meta-analysis of clinical trials of PD-1 and PD-L1 inhibitors highlighted a
DIILD incidence rate of 3.6% for PD-1 inhibitors (nivolumab, pembrolizumab) and 1.1% for PD-L1
inhibitors (avelumab and durvalumab) [52,53]. The incidence rate, severity and mortality of DIILD
were all higher for PD-1 inhibitors compared with PD-L1 inhibitors, with a DIILD mortality rate of 8%.
No association with dose or duration of treatment was observed [52].
Another observational study of 1826 cancer patients treated with checkpoint inhibitors reported
a DIILD incidence rate of 3.5% [51], and a mortality rate of 9.4% for DIILD cases, which is similar to
clinical trial data. Time to onset ranged from 0.2 to 27.4 months, with 42% occurring within 2 months
of starting treatment. When used in combination therapy, the rates of DIILD were increased compared
to single-agent use [54].
3.2.2. Rheumatological Therapy
In rheumatology, analyses of DIILD are hampered by a background prevalence of ILD, especially
in rheumatoid arthritis (RA). Furthermore, many DMARDs are immunosuppressive and associated
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with an increased risk of opportunistic infection, providing challenges in the differential diagnosis of
worsening respiratory symptoms.
Methotrexate (MTX)
MTX is a mainstay agent in rheumatology and for the treatment of lymphomas and sarcomas.
The incidence of DIILD in RA patients receiving low-dose MTX has been reported as 0.3–2.1% [55,56]
Two meta-analyses compared rates of DIILD following MTX to other DMARDS in RA and non-RA
inflammatory diseases [55,57]. In RA, the DIILD rate with MTX exposure was 0.28% (13/4544)
compared to 0/4040 for other DMARDs (relative risk (95% CI) = 7.81 (1.76–34.72)) [55]. In the
non-RA population, no increased risk was seen in MTX-treated patients [57]. Interestingly, no events
were reported after 2002 in the RA meta-analysis, suggesting potential reporting bias or historic
over-estimation of risk [55].
MTX-induced DIILD has a variable time and rate of onset and is not apparently
dose-dependent [56,58,59]. In one study, 48% of cases developed within 32 weeks of treatment
initiation [60]. Kremer et al. noted a mean time to onset of 23 days (range 3–112) [61]. Others, however,
noted cases occurring up to 4 years after starting treatment, or after treatment cessation [60]. DIILD
has also been reported to recur in approximately one-third of re-challenged cases [60,61] and carries a
high mortality (10–30%) [59–61].
Leflunomide
Most reported data are from Japan. In one post-marketing surveillance study of 5045 Japanese
patients taking leflunomide, new ILD occurred in 1.2%, and pre-existing ILD deteriorated in 5.7%
of cases [62]. Most patients presented within 20 weeks of treatment initiation in one study [63].
Leflunomide-related mortality was 19% and 41% in two studies [63,64]. In a nested case-control study,
Suissa et al. noted significant channelling bias which may explain some of the increased risk with
leflunomide [65]. However, use of a loading dose and low body weight were significantly associated
with DIILD, suggesting leflunomide toxicity [62,65]. Pre-existing ILD, smoking and prior MTX use
have also been reported to increase DIILD rates for leflunomide [62,65]. Following a medical alert
advising against drug loading and caution in patients with low body weight or pre-existing ILD,
the incidence of ILD was reported to have reduced from 1.46% to 0.63% [62]. Conway et al. found
no increased rate of adverse pulmonary reactions from leflunomide in a meta-analysis of clinical
trials [66].
Biological DMARDs
Numerous cases of suspected DIILD associated with anti-tumour necrosis factor (TNF)
agents have been published, although definitive evidence of causation remains controversial [67].
Post-marketing surveillance data from Japan reported an incidence rate of 0.6% for new or progressive
ILD in patients treated with anti-TNF therapy [68]. This study did not have a control arm. Cohort
studies have not demonstrated a difference in rates of incident ILD between patients treated with
anti-TNF agents and other types of DMARD, but there are no observational studies which compare
rates of DIILD [69,70]. In a review of published case reports, 15/52 (29%) patients with ‘DIILD’ on
anti-TNF therapy died during follow-up, with 70% of deaths occurring within 5 weeks of symptom
onset [71]. Mortality was highest in older patients, those with pre-existing ILD or those receiving
concomitant immunosuppression. Two systematic reviews highlighted cases of potential DIILD
associated with other biologic DMARDs, including tocilizumab (an interleukin 6 inhibitor) and
rituximab [67,72]. Three systematic reviews included published cases of rituximab-induced ILD
ranging from 7 to 45 cases [72–74]. The majority of cases were oncology patients presenting with
acute or subacute ILD around the fourth cycle of treatment. Case fatality ranged between 18% and
37.5% [72–74].
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3.2.3. Other Drug Classes
Antibiotics
Nitrofurantoin is commonly used for the treatment and prophylaxis of urinary tract infections.
DIILD accounts for 16–48% of nitrofurantoin-related adverse events reported in registry studies [75,76].
In a Swedish registry study of 447 nitrofurantoin-related DIILD, almost 90% were acute reactions [76].
The hospitalisation rate was 75% and mortality rates were 0.5% and 8%, respectively, for patients with
acute lung reactions and chronic interstitial pneumonia [76].
An acute pulmonary reaction can occur within days of initiation, or within hours if there has
been previous nitrofurantoin exposure [77]. The underlying mechanism is believed to be an acute
hypersensitivity reaction, and most cases resolve quickly [77]. Chronic interstitial pneumonia is a rarer
presentation mimicking pulmonary fibrosis [75–77], and is more common in patients on long-term
prophylaxis [76]. Santos et al. performed a case-control study comparing DIILD with nitrofurantoin
use compared to other antibiotics [78]. Overall, the relative risk (RR) of DIILD was not increased for
nitrofurantoin. The absolute risk was higher for chronic compared to acute nitrofurantoin therapy (RR
1.53 chronic vs. acute use, p < 0.05), and for older patients (age >85 relative risk 1.99 for age 85 vs. <85,
p < 0.05).
Regarding other antibiotics, daptomycin—an antibiotic usually reserved for life-threatening
Gram-positive bacteria—has been associated with a risk of eosinophilic DIILD. In a retrospective study,
3/102 daptomycin-treated patients developed DIILD with eosinophilia [78]. A review of the Food
and Drug Administration (FDA) pharmacovigilance database identified 7 definite, 23 probable and
38 possible cases of daptomycin-induced eosinophilic pneumonias between 2004 and 2010 [79]. All
patients in this series recovered.
Amiodarone
Amiodarone is one of the most common causes of DIILD in registries [10], with a reported
incidence of 1.2–8.8% [80–84] and mortality of 3–37% [80–84]. A retrospective study of 500 patients
treated with amiodarone in Japan identified 40 patients (8%) with DIILD occurring during a mean
follow-up of 48 months [85]. The cumulative incidence at 1, 3 and 5 years was 4.2%, 7.8% and 10.6%,
respectively, with an estimated annual incidence of 2.1%. Patients most commonly present with
subacute DIILD [86,87]; however, an acute, frequently fatal form can occur [80]. One study evaluating
90-day outcomes in patients hospitalised for amiodarone-associated DIILD reported a 37% mortality
rate with a median time to death of 17 days. Symptomatic recovery in survivors occurred over a
median of 36 months, with improvement in radiological features of alveolitis but a high rate of fibrosis
(66%).
Cumulative dose is an important risk factor for amiodarone-related DIILD, and the combination
of high doses over longer periods is more strongly associated with DIILD than dose or duration
alone [88].
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Table 2. Summary of specific classes or agents associated with DIILD identified from literature review of lung disease.
Drug/Class Number of Studies Quality Study Design Patient Population
Sample Size
(Range)
Case Definition
of DIILD
Estimated
Incidence
(Range)
Estimated
Mortality in
Those with
DIILD (Range)
Cancer Therapies
Bleomycin
[18–24]
7
Moderate = 3
Low = 3
Very low = 1
Meta-analysis = 2
Observational studies = 5
Various cancers (1
meta-analysis in ovarian sex
cord stromal tumours and 1 in
all cancer RCT data)
22–1147 variable
Meta-analyses:
6.8–15%
Other studies:
6.8–21%
Meta-analyses:
8.1–23%
Other studies:
0–48%
Gemcitabine
[13,25–32]
9
Moderate = 2
Low = 6
Very low = 1
Meta-analysis = 2
Clinical trial = 3
Observational = 4
Cancer (predominantly
pancreatic and non-small cell
lung cancer but also others)
Meta-analysis:
1308–1742
Others: 26–2440
variable 1.1–3.9% 0–22%
Epidermal growth factor receptor-targeted therapies (EGFR)
Erlotinib
[34–36,89,90]
5
Moderate = 2
Low = 3
Meta-analysis = 2
Post marketing
surveillance = 2
Observational = 1
Non-small cell lung cancer 341–9909 variable 0.9–5.9% 31–45%
Gefitinib [34–37] 4
Moderate = 2
Low = 2
Meta-analysis = 2
Post marketing
surveillance = 2
Non-small cell lung, breast and
colorectal cancer
70–5468 variable 1.9–3.5% 18–44%
Panitumumab
[33,39]
2 (but reporting
from same cohort)
Moderate = 2
Post marketing
surveillance
Colorectal cancer 3085
Expert case
review
1.3% 51.3%
Cetuximab [38] 1 Moderate = 3
Post marketing
surveillance
Colorectal cancer 2006
Physician
reported
1.2% 41.6%
Mechanistic target of rapamycin protein (MTOR) inhibitors
Everolimus [40–
43,45,46,48,49]
8
Moderate = 3
Low = 3
Very low = 2
Meta-analysis = 1
Clinical trial = 2 (same
trial 2 separate published
analyses)
Observational = 5
Neuroendocrine cancer
Renal cell cancer
Renal transplant
40–2261
Variable,
including
radiographic
signs of DIILD
2.8–58% 5.4–20%
Temsirolimus
[44,47]
2 Low = 2
Meta-analysis = 1
Clinical trial = 1
Observational study = 1
Neuroendocrine cancer
Endometrial cancer
Renal cell cancer
22–408 Variable 29–36% n/a
Sirolimus [48] 1 Very low = 1 Observational Renal/pancreas transplant 115
Physician
reported
9.5% 0%
Check point inhibitors (CPI)
All CPIs [51–53] 3
High = 2
Moderate = 1
Meta-analysis = 2
Observational = 1
Non-small cell lung cancer 1826–3232 variable 1.1–3.6% 8–9.4%
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Table 2. Cont.
Drug/Class Number of Studies Quality Study Design Patient Population
Sample Size
(Range)
Case Definition
of DIILD
Estimated
Incidence
(Range)
Estimated
Mortality in
Those with
DIILD (Range)
Ipilimumab [91] Low = 1 Observational = 1 Melanoma 146
Radiographic
evidence of
DIILD
5.44% n/a
Nivolumab [92] 1 Low = 1
Post hoc pooled clinical
trial analysis = 1
Cancer (various types) 170
Physician
reported events
11.7% 0%
Other agents identified
Irinotecan [93] 1 Low = 1
Post marketing
surveillance
Cancer (various types) 8864
Physician
reported
0.74% 24%
Rituximab
[67,72–74]
4 Very low = 4
Systematic reviews = 3
Case series = 1
Predominantly cancer but
other indications included
16–52 Variable n/a n/a
Imatinib [94] 1 Low = 1
Post marketing
surveillance
Leukaemia 6
Physician
reported
n/a 6/6 resolved
Pemetrexed [95] 1 Moderate = 1
Post marketing
surveillance
Mesothelioma
Non-small cell lung cancer
903
Expert
committee
review
1.8%
Granulocyte
colony
stimulating
factor [96]
1 Low = 1 Observational
In conjunction with
chemotherapy
40 treated vs. 25
with
chemotherapy
along
Physician
reported
0.2% vs. 0% in
the control
group
n/a
Rheumatology drugs
Methotrexate
[55–61,67]
8
Moderate = 3
Low = 4
Very low = 1
Meta-analysis = 2
Clinical trial = 3
Observational = 2
Case series = 1
Rheumatoid arthritis
Psoriasis, psoriatic arthritis or
inflammatory bowel
Primary biliary cirrhosis
29–3188 variable 0.06–15% 10–33%
Tumour
necrosis factor
inhibitors
[67–72,97,98]
8
Moderate = 4
Low = 1
Very low = 3
Post marketing
surveillance = 3 (2 papers
report on 1 study)
Observational study = 3
Systematic review of case
reports = 3
Predominantly rheumatoid
arthritis but cases in other
diseases
233–13,894 variable 0.6% 32%
Leflunomide
[62–66]
5
Moderate = 1
Low = 3
Very low = 1
Meta-analysis of RCTs = 1
Case control via claims
database = 1
Post marketing
surveillance = 2
Case series = 1
Rheumatoid arthritis 2274–62,734 variable 0–1.2% 19–41%
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Table 2. Cont.
Drug/Class Number of Studies Quality Study Design Patient Population
Sample Size
(Range)
Case Definition
of DIILD
Estimated
Incidence
(Range)
Estimated
Mortality in
Those with
DIILD (Range)
Cardiology drugs
Amiodarone
[80–88,99–101]
12
Moderate = 2
Low = 5
Very low = 5
Observational = 7
Case series = 5
Cardiovascular disease 13–500
Variable, often
not restricted to
DIILD
1.2–8.8% 0–41%
Bepridil [102] 1 Low = 1 Observational Cardiovascular disease 222
Standardised
definition
6.3% 0%
Statins [103] 1 Very low = 1
Observational (Adverse
events reporting
database)
Cardiovascular
disease/prevention
1/40 adverse
event reports for
statins were ILD
n/a
Anti-infection agents
Nitrofurantoin
[75–78,104]
5
Low = 3
Very low = 2
Case-control study = 1
Registry study = 1
Post marketing
surveillance = 1
Case series = 2
Chronic and acute treatment of
urinary tract infection
10–70,804
Variable, some
used “any ILD”
after use of drug
3.65% 1.34%
Daptomycin
[79,105]
2 Low = 2
Observational study = 1
Post marketing
surveillance = 1
Infection (one study
specifically infective
endocarditis)
58–102 Variable 2.9% n/a
Interferon [106] 1 Very low = 1
Systematic review of case
reports
Hepatitis C 25 Variable n/a n/a
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3.3. Risk Factors for the Development of DIILD
Risk factors for the development of DIILD vary according to the disease, drug and population
being treated. Certain risk factors have featured prominently across drugs.
Age: Increased age has been identified as a significant risk factor for DIILD for treatment with
bleomycin, gemcitabine, EGFR-targeted agents, leflunomide, MTX, amiodarone and nitrofurantoin [23,
30,33,58,62,76,77,85,95,104,107]. For bleomycin, dose reductions are recommended together with
weekly chest radiographs and close follow-up after completion of therapy to monitor for DIILD in
patients >60 years old. In contrast, no age association has been found with MTOR inhibitors [42,52,62].
Pre-existing lung disease: Pre-existing ILD or Idiopathic Pumonary Fibrosis (IPF) is an
independent risk factor for DIILD with a wide range of agents [13,34,45,67,89,91,95,108,109]. For
example, in NSCLC patients, prior ILD was associated with a 3.19-fold increased risk of DIILD in
Japan [34]. Increased DIILD risk has also been associated with pre-existing Chronic Obstructive
Pulmonary Disease (COPD), bronchiectasis and asbestosis [34,95,109,110].
Smoking: Smokers are at increased risk of DIILD when treated with gemcitabine, EGFR-targeted
agents and methotrexate [20,33,56,58,95,108–112].
Drug dose: A clear dose-dependent relationship is well recognised for bleomycin, amiodarone
and nitrofurantoin and is described in the Common Causative Drugs section. However, findings are
not consistent for other agents across studies [41,45].
Underlying disease characteristics: In oncology, poor performance status and advanced or
metastatic stages of disease are independent risk factors for DIILD [30,33,107,110]. One Japanese
post-marketing study observed a 3-fold higher risk of DIILD for patients with NSCLC treated with
gemcitabine compared to other cancers treated with gemcitabine [30]. Whilst there may be confounding
due to a higher incidence of pre-existing ILD in NSCLC, this difference was not observed in studies
of other agents used for this indication [46,95]. In RA, methotrexate DIILD risk was increased in
patients with high inflammatory markers, low albumin, extra-articular disease and high levels of
disability [67,111].
Sex: Male sex has been reported as a risk factor for DIILD in some studies following treatment
with EFGR inhibitors, pemetrexed, methotrexate and amiodarone [33,58,85,95].
Other therapies: For gemcitabine, prior chemotherapy carried a relative risk of DIILD of 1.45 [30,
33]. Conversely, two studies (one in erlotinib-treated and one in immune checkpoint inhibitor-treated
patients) found that re-treatment with the same drug or another drug in the same class actually carried
a lower DIILD risk [34,52]. Prior thoracic radiotherapy also increased DIILD risk in lung cancer
patients [34]. In RA, prior MTX exposure increased the risk of leflunomide-induced ILD [65], and
prior DMARD therapy was independently associated with a higher risk of MTX-induced DIILD [58].
However, such studies may be confounded by such patients having more severe or progressive disease.
Other risk factors: Other potential risk factors for DIILD include genetic susceptibility, higher
alcohol consumption, renal dysfunction and diabetes [26,34,58]. Certain (Cytochrome P450) CYP
enzyme polymorphisms increase the risk for drugs metabolised by CYP enzymes, and certain (human
leukocyte antigen) HLA allelic variants have been linked with DIILD following erlotinib–gemcitabine
combination therapy [113,114]. Weiner et al. reported that patients switching to sirolimus at a later
stage of anti-rejection treatment were at higher risk of DIILD, as were patients with impaired renal
function [115]. Higher rates were also observed in Japanese patients, and this may be a combination
of genetic susceptibility and variation in reporting, which has been observed between different
countries [5].
3.4. Radiological Investigation of DIILD and Prevalent Radiopathological Patterns
Unilateral or, more commonly, bilateral pulmonary infiltrates on a chest radiograph may be the
first indication of DIILD [116]; however, 25–75% of chest radiographs are normal in cases of clinically
suspected DIILD [89,116,117].
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CT has higher sensitivity for detecting ILD features and is the imaging modality of choice [45,118].
The main limitations are exposure to ionising radiation, an issue minimised with modern scanners and
the use of iterative reconstruction. To date, CT assessments have been non-specific for DIILD, as the
numerous patterns of interstitial change are commonly seen in other ILDs.
Formal studies assessing CT in DIILD are limited by inconsistent terminology, many having been
conducted prior to the current ATS/ERS ILD classification [1]. Pathological terms such as chronic
interstitial pneumonia (CIP) are common in older imaging studies [14–16], but they have limited
utility due to relatively poor agreement between radiological and pathological findings [15,119].
Several studies have compared histopathological and imaging findings in DIILD [12,15,16,73,119,
120]. A prospective study of 42 patients with DIILD undergoing transbronchial lung biopsy (TBLB)
or bronchoalveolar lavage (BAL) reported an overall diagnostic agreement of 67% [15], while a
retrospective analysis of patients with DIILD undergoing TBLB (n = 4) or open biopsy (n = 16) at a
single centre reported a lower diagnostic agreement (45%) [119]. In contrast, CT features of diffuse
alveolar damage (DAD) are highly congruous with histopathological features of DAD [1] and confer
high mortality [33,39,80,90,94,95,121,122]. In general, the correlation imaging pattern of CT and
pathology is suboptimal [119].
DIILD most commonly manifests as ground glass opacification (GGO) with or without
consolidation [16,17,44,80] and has a basal, peripheral and bilateral distribution, often affecting
multiple lobes [43,91,92]. Heterogeneity in reporting makes the true incidence of each pattern
difficult to establish. Changes resembling organising pneumonia (OP) are most commonly reported,
followed by non-specific interstitial pneumonia (NSIP) and hypersensitivity pneumonitis (HP)-like
changes [12–15,33,34,39,43,73,90–94,122]. NSIP is reportedlymore common in hospitalised patients [12]
and in chemotherapy-induced DIILD [12,13]. Reticular changes and volume loss (termed CIP in older
studies) occur less commonly [73]. In the modern classification, this is most closely aligned with
fibrotic NSIP or usual interstitial pneumonia (UIP) [1]. In some cases, hilar lymphadenopathy and
pleural effusions were found, often when associated with eosinophilia [123]. Appearances consistent
with sarcoidosis have been reported in at least six cases following treatment with interferon-alpha [15].
Another pattern of ground glass opacities with interlobular septal thickening, termed “crazy paving”,
is recognised in DIILD, but is neither sensitive (present in 12% of DIILD) nor specific, as it is common
in the context of heart failure [123].
Qualitative CT features are not specific to DIILD, as other causes of these radiological
patterns, such as atypical infections (particularly in immunosuppressed patients) or connective tissue
disease-associated ILD, may confound interpretation [44,45]. In addition, the radiological patterns
of DIILD for the same drug are highly variable (e.g., NSIP, DAD and COP patterns are seen in
amiodarone-induced ILD [30]) and, conversely, the same pattern can be a feature of numerous drugs
(e.g., OP-like pattern is seen in a number of agents, including EGFR RTKIs, checkpoint inhibitors and
amiodarone [39,51,84]).
3.5. Non-Imaging Diagnostic Investigations
3.5.1. Pulmonary Physiology
Pulmonary physiology is important in the assessment of suspected DIILD but, like CT, lacks
specificity. Reduction in DLCO is a presymptomatic feature of DIILD, and changes in FVC correlate
with clinical progression in bleomycin-treated patients [18,124]. The sensitivity of pulmonary function
tests (PFTs) varies within studies. One historic study in suspected bleomycin lung reported abnormal
PFTs in only 31/150 patients [18]. Yamada et al. evaluated the diagnostic accuracy of percentage
change in DLCO in patients treated with amiodarone [85]. Sensitivities of 76%, 68% and 59% were
found for a 10%, 15% and 20% reduction in DLCO, respectively. In a study of nitrofurantoin-induced
DIILD, all patients had impaired DLCO but only 2/17 had abnormal FVC [77].
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3.5.2. Bronchoalveolar Lavage (BAL)
BAL findings, including raised lymphocyte, neutrophil and eosinophil counts [122,125–127], are
not specific for DIILD, as they also occur in types of inflammatory or infective lung disease [126].
Reversal of the CD4:CD8 lymphocyte ratio has been reported in some, but not all, studies, but again is
not specific for DIILD [127–130]. Other reported findings include cellular abnormalities, such as nuclear
enlargement and hyperchromasia, lipid inclusions and haemosiderin-laden macrophages [15,131]. The
presence of reactive type II pneumocytes has also been described in severe cases of DIILD [16].
Opportunistic infection is high on the differential diagnosis of most DIILD. In some studies,
positive BAL microbiology led to a revised diagnosis in suspected DIILD cases [41,111,116,132]. In a
study of 26 everolimus-treated patients initially diagnosed with DIILD, 12 (46%) were subsequently
diagnosed with Pneumocystis jiroveci [41]. Currently, the key role of BAL is to aid in the exclusion of
other causes, especially infection.
3.5.3. Lung Biopsy
The role of lung biopsy has been limited to small studies, and almost all histopathological patterns
have been reported in DIILD; however, none are specific for DIILD [15,16]. There is, therefore, limited
evidence for the routine use of biopsy in the diagnosis of DIILD but, like BAL, it may be useful in
selected cases where there is diagnostic uncertainty or to exclude other causes.
3.5.4. Circulating Biomarkers
Krebs von den Lungen-6 (KL-6) is a mucin-like glycoprotein secreted by type II alveolar
pneumocytes and bronchial epithelial cells in response to damage and regeneration in the context of
ILD. In a prospective study, increased KL-6 was observed in 53% of DIILD patients and correlated with
the DAD pattern and more extensive lung involvement [14]. Changes in KL-6 over time corresponded
with the clinical course. A second study reported a predictive association between the ratio of KL-6 to
sialyl SSEA-1 (SLX) and subsequent DIILD in lung cancer patients undergoing chemotherapy [90]. The
specificity of KL-6 in DIILD has not, however, been established. Other biomarkers, including peripheral
eosinophilia and raised inflammatory markers, are non-specific and not diagnostic for DIILD.
3.6. The Role of Glucocorticoids (GCs) in the Treatment of DIILD
Our review was limited by a lack of randomised data, missing data on dose and duration,
and variation in criteria for patient selection and dose. Assessing the impact of GC therapy on
resolution of DIILD or survival was also hampered by the common practice of introducing steroids
contemporaneously with the withdrawal of the offending drug. Table 3 summarises studies where
either dosing information and/or outcomes from GC treatment were available.
3.6.1. Efficacy
The reported efficacy of GC treatment in DIILD varied widely. In a series of 75 cancer patients
with irinotecan-induced DIILD treated with GC, 46 (61%) recovered and 22 (29%) died [93]. In 10
pemetrexed DIILD patients treated with GC, five patients (50%) responded, four (40%) failed to
respond and one died [95]. Rebattu et al. also reported 100% recovery after drug discontinuation and
GC therapy in six DIILD cases associated with combination gemcitabine and docetaxel therapy [133].
In one series of all-cause DIILD, 62% (29/47 patients) received GCs and the remaining 18 patients
recovered without supportive GC therapy [12]. The retrospective nature of these studies and the lack
of specific criteria for the use of GC means there is a high risk of channelling bias, i.e., GCs tend to be
used more commonly in those with severe disease and a DAD pattern.
J. Clin. Med. 2018, 7, 356 16 of 30
3.6.2. GC Dose and Duration
GC doses ranged widely and included high-dose oral and IV methylprednisolone regimes, with
dosing and duration in part guided by the radiological pattern [59,134]. Takatani et al. reported a
median cumulative dose of 5240 mg prednisolone for DAD, compared to 2722 mg for OP, 415 mg for
HP and 264 mg for NSIP groups [122]. Weak supportive evidence for the role of GCs is suggested
by an increased risk of DIILD relapse when GCs are stopped or tapered early (within 3 months of
onset) [80,116]. The merit of high dosages is not established.
3.6.3. DIILD Subsets and GC Responses
The DAD pattern has the poorest prognosis, and, in one series, no DAD patients improved with
GC treatment, and the overall mortality was 37.5% [12]. Reported improvements with GC therapy for
other radiological patterns were: 75% (3/4 patients) for OP, 45.8% (11/24 patients) for NSIP and 36.4%
for HP pattern [12].
Although GC therapy was used in many studies, there is currently no evidence on which to
base recommendations for GC use in DIILD. The use of GC in therapy is recommended in severely
affected patients, with dosing regimens at the discretion of the attending physician. Further studies
are required in order to develop more detailed treatment recommendations.
3.7. Prognosis
DIILD prognosis varies between drugs and different studies. Complete recovery is possible
following dose reduction, drug withdrawal and/or concomitant GC use [17,34,45,73,91,110].
Nevertheless, a significant proportion fails to improve, or follows a progressive clinical course [29,
34,91,110]. DIILD mortality is often due to respiratory failure, multiorgan failure, progression of the
primary underlying disease or as an adverse effect of GC therapy (e.g., infection) [80,106]. In the
context of oncology, mortality ranges from 14 to 51.3% [13,22,30,33,34,40,93,109], whilst in non-cancer
settings, mortality ranges from 0 to 41% [26,59–61,63,64,71,106].
Factors Predicting Mortality
Clinical characteristics: Acute and severe presentations are the most consistent predictors of
mortality. In particular, a requirement for mechanical ventilation is associated with mortality rates of
>60% [135,136]. Rapid symptom onset, higher initial disease severity and hypoxaemia at presentation
also predict mortality [63,64,80]. Pre-existing ILD, male sex, age >65 years and a diagnosis of NSCLC
are also associated with higher case fatality rates [93]. In NSCLC patients, a poor performance status
(2–4), ≥2 prior chemotherapy regimens and <50% remaining normal lung area also predict DIILD
mortality [34,108].
Radiological patterns: For CT, a greater extent of lung injury and a homogenous pattern are
associated with higher mortality in amiodarone-treated patients [106]. DAD and NSIP patterns
also predict poorer outcomes [80,119] (with the DAD pattern, 40–83.3% mortality) [33,34,95].
Honeycombing with interstitial pneumonia is also associated with higher mortality [34]. Of note,
however, is that full recovery has been seen with diffuse ground glass opacities [95], and some studies
have not found CT patterns to be prognostic [119,135].
Other: For BAL, the presence of desquamated type II pneumocytes is associated with
mortality [16]. Others have also found that circulating and/or BAL KL-6 and heat shock protein
47 are associated with higher mortality [12,119,121,122]. Their association with a more severe clinical
presentation and with DAD, however, means that their incremental value as prognostic markers
remains unclear.
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Table 3. Summary of studies which included information on use of glucocorticoids.
Author Drug
Patient
Population
Sample Size Glucocorticoids Dose (Oral or IV) Response
Mankikian et al.
[80]
Amiodarone DIILD 46
Median dose of 1 mg/kg
15 surviving patients followed and 9 (60%)
received glucocorticoids for 3–29 months.
All surviving patients successfully had
glucocorticoids withdrawn
76% got glucocorticoids but no obvious difference in
survival outcomes. Three patients treated for <3
months relapsed and glucocorticoids restarted. No
relapse in patients treated for >6 months
Kakugawa et al.
[12]
Various DIILD 47
29 of 47 patients received glucocorticoid therapy.
Decision on glucocorticoid therapy was
physician-based rather than protocol-based.
No dosing information available
None of the patients with a DAD pattern on HRCT
improved with glucocorticoid treatment, and DAD
group had a 37.5% mortality. 75% of those with OP
pattern on HRCT (3 of 4) improved with
glucocorticoid treatment. With an NSIP pattern, 45.8%
(11 of 24 patients) improved with glucocorticoid
treatment. Hypersensitivity pneumonitis (HP) pattern
was associated with a 36.4% response to
glucocorticoid therapy.
Ki et al. [134]
Bleomycin with
cisplatin and
vincristine
Cervical cancer
patients treated
with prior
mentioned
agents [59]
61 (7 cases of
DIILD)
4 with bleomycin injury received glucocorticoid
Different regimens within the study.
1 patient who improved received 40 mg/day
methylprednisolone, followed by 10 mg daily.
2 acutely ill patients received IV
methylprednisolone 500 mg/day × 3 days.
1 patient received 1 mg/kg/day prednisolone,
then 0.5 mg/kg
Of these 4 patients, 2 died, 1 improved, 1
non-responder.
Insulin-dependent diabetes developed in 2 patients
Kim et al. [105] Daptomycin Suspected DIILD
58 (7 definite
DIILD cases, 13
probable cases)
No dosing information
Definite cases: 5 of 7 received glucocorticoid (1
intravenous)
Probable cases: 9 of 13 received glucocorticoid
No deaths
1 required long-term treatment
Rebattu et al. [133]
Gemcitabine with
docetaxel
NSCLC patients
treated with
prior mentioned
agents
49 (6 DIILD
cases)
6/6 received glucocorticoids All recovered
Ohnishi et al. [94] Imatinib DIILD 27
19/27 received high dose glucocorticoids
5/27 moderate dose glucocorticoids3/27 no
treatment
7/27 resolved
16/27 improved
4/27 no improvement
Sharma et al. [59] Methotrexate
Primary biliary
cirrhosis patients
treated with
methotrexate
43 (6 DIILD
cases)
5/6 received prednisolone 60 mg IV daily
Duration of intravenous route and
glucocorticoids taper unclear
4/5 given glucocorticoids responded,
1 patient died from liver decompensation
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Table 3. Cont.
Author Drug
Patient
Population
Sample Size Glucocorticoids Dose (Oral or IV) Response
White et al. [45] Everolimus
Advanced renal
cell cancer
patients treated
with everolimus
416 (37 DIILD
cases)
16/37 patients received glucocorticoids
All 10 patients with grade 3 pneumonitis
received glucocorticoids
10 patients with grade 3 pneumonitis who received
glucocorticoids
3/10 continued everolimus: 1 died and 2 recovered
7/10 discontinued: 5 recovered, 1 had ongoing
disease, 1 died
Tomii et al. [95] Pemetrexed
Mesothelioma
and NSCLC
DIILD patients
1586 (10 DIILD
cases)
10 cases, all of which received glucocorticoids
5/10 patients deemed glucocorticoids responsive, 1
indeterminate, 4 non-glucocorticoids responders died
Osawa et al. [33] Panitumumab
Colorectal cancer
patients treated
with
panitumumab
3085 (39 DIILD
cases)
No dosing information available
Minimal information on glucocorticoid impact other
than statement that most of the 20 patients who died
had received glucocorticoids
Yoshii et al. [93] Irinotecan
Cancer patients
treated with
irinotecan
8864 (153 DIILD
cases, 83 with
clinical
information)
75/83 patients received glucocorticoids
No dosing information available
46/75 of those treated recovered or improved, 5/75
no response, 22/75 died, 2/75 unknown outcome
DAD pattern associated with lack of response to
glucocorticoids
Liote et al. [73] Rituximab DIILD 45
27/45 cases of rituximab DIILD received
glucocorticoid. Dosing unclear.
Some patients received 1 mg/kg of body weight
concomitantly with re-challenge.
No recurrence of rituximab injury in 3 patients
receiving re-challenge with rituximab and
concomitant 1 mg/kg methylprednisolone
Early onset acute presentation: 5 patients all received
glucocorticoids, 2 died
Late onset chronic presentation in 3 patients who
recovered with glucocorticoid therapy
Authors recommend longer period of glucocorticoids
usage rather than just boluses at each rituximab
infusion, and a gradual taper to avoid rebound
Takatani et al.
[122]
Various DIILD
DAD group received median cumulative
glucocorticoids dose of 5240 mg, range
1000–9195 mg; NSIP group median of 264, range
0–735 mg; HP group median 415, range 0–4470
mg; OP group median 2722, range 0–7835 mg
Days of oxygen therapy correlated well with
cumulative doses of glucocorticoid therapy, i.e., the
sicker patients received more glucocorticoids. OP
pattern patients showed full recovery with
glucocorticoids. No deaths in this group of 34
non-chemotherapy DIILD pts. 11 pts recovered fully
without glucocorticoids
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Table 3. Cont.
Author Drug
Patient
Population
Sample Size Glucocorticoids Dose (Oral or IV) Response
Chap et al. [116]
Cyclophosphamide,
cisplatin and
BCNU
Breast cancer
patients treated
with prior
mentioned
64 (37 cases of
DIILD)
37/37 treated with prednisolone 60 mg oral
twice daily × 10 days, then 30 mg/day × 1
week, 20 mg/day × 1 week, 15 mg/day × 1
week, followed by 5 mg taper on daily dose each
week.
Initiation of prednisolone based on scoring
system; crackles on lung auscultation = 2, drop
in DLCO by >10% from baseline = 3, drop in O2
saturation ≥4% with 2 min walk = 3, interstitial
infiltrates on CXR = 3. Patients with a score ≥6
received prednisolone as above.
Glucocorticoid therapy associated with rapid clinical
improvement in “most patients” (absolute numbers
not available). 11 patients required prolonged
prednisolone therapy (4–8 months), having
experienced exacerbation of symptoms when
prednisolone reduced to 15–20 mg/day
Hamada et al. [30] Gemcitabine
pancreatic, lung,
urothelial, breast,
ovarian
25,924 (428 cases
of ILD not
verified as
DIILD)
363/428 (84%) patients with ILD received either
oral or intravenous glucocorticoids
20% of hospitalised DIILD patients with severe
disease died, no data on glucocorticoid-treated group
outcome versus non-glucocorticoid-treated patients
Abbreviations: DILD = Drug induced Interstitial Lung Disease; DAD = Diffuse alveolar damage; HRCT = High resolution Computer Tomography; OP = Organising Pneumonia; NSIP =
Non specific interstitial pneumonia. And HP = Hypersensitivity pneumonitis.
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4. Discussion
DIILD may affect a wide spectrum of patients globally, with a significant impact on survival in
multiple contexts. Evidence on the true incidence and mortality, case definition, diagnostic tests and
optimal treatment of DIILD is lacking. The TRISTAN Consortium has set out to address some of these
gaps, and this systematic review provides a baseline assessment of what is already known about this
condition and Table 4 highlights the key findings of this PRISMA compliant systematic review.
Few studies have examined the incidence rates in the general population, and the available
pharmacovigilance studies likely significantly underestimate the risk. A significant risk of DIILD
has been demonstrated with newer agents, such as EGFR-targeted therapies, highlighting the
urgent need to investigate the true scale of DIILD and its impact on treatment and mortality in
a contemporaneous population.
Whilst we identify a large number of relevant papers in this review, the majority of studies were
of low quality, with a high risk of bias. The lack of standardised case definition used across studies
made it impossible to pool data and conduct a formal meta-analysis. While a large number of studies
reported rates of new ILD occurrence and pulmonary toxicity with specific agents, there was a lack
of high-quality studies investigating DIILD in a non-agent-specific setting. Other significant factors
limiting our ability to draw firm conclusions included the over-representation of some geographical
areas, such as Japan, where rates of ILD and reporting methods may differ from other parts of the
world. There was also significant confounding in a number of studies, and limitations in study design
and sample size all added to difficulties in data synthesis.
From published data, there are no radiopathological patterns specific to DIILD and there are
no investigations which, alone or in combination, can be confidently used to diagnose DIILD.
Imaging with CT plays an important role in the identification of lung changes, and bronchoscopy is
helpful for excluding infection. All tests, however, lack specificity in DIILD; therefore, the diagnosis
largely remains one of exclusion. The lack of specific diagnostic markers for DIILD has an impact
on drug development, particularly in cancer and rheumatology populations, which have a high
background prevalence of ILD and significant respiratory infection risk. Better biomarkers to detect
early safety signals and to distinguish between disease and drug-related ILD are needed. More specific
imaging biomarkers derived from quantitative CT analyses, positron emission tomography or MRI
(e.g., hyperpolarised 129Xe MRI, oxygen-enhanced MRI, dynamic contrast-enhanced MRI) better
characterise lung structure and function, and may facilitate the development of biomarkers specific to
DIILD [137–139].
Evidence for managing DIILD was distinctly lacking. In some studies, agents were continued
even with grade 3 DIILD [45]. The risk of development and progression of DIILD must always be
balanced against the negative impact of stopping the drug on outcomes/survival, and this delicate
balance may vary depending on the condition and treatment efficacy. The literature had no consistent
approach to decision making on drug withdrawal and no robust evidence base for the use of GCs. We
found a number of possible risk factors for the development of DIILD and prognosis, which could be
considered when developing a consensus on the management approach. We have identified points
to consider in any approach to GC use in DIILD. However, prospective studies are required, with
more detailed recommendations needed to aid decision making on drug initiation, withdrawal and
monitoring in high-risk groups.
It is important to note that this review does not provide a comprehensive catalogue of all drugs
implicated in the causation of drug-induced lung disease, specifically as we excluded case reports
and studies with a sample size of less than 10. The most recent data from the comprehensive website
Pneumotox (www.pneumotox.com) highlight 1406 drugs, substances or procedures reported as having
caused pulmonary injury (personal communication Ph Camus through his website, 3 October 2018).
Approximately 800 of these agents/procedures had less than 10 reports on the website. While not
all of these substances are licensed drugs nor cause an interstitial lung disease pattern of injury, this
underlines a limitation of the current review.
J. Clin. Med. 2018, 7, 356 21 of 30
Overall, this systematic review informs the formulation of a research agenda in DIILD, and we
propose several key areas for further investigation and development, including:
(i) A standardised case definition for the study of DIILD to be used in clinical trials and
observational studies.
(ii) Validation of better biomarkers for detecting early DIILD and discriminating from other causes
of ILD.
(iii) An evidence base for the management of DIILD, including through clinical trials to the efficacy
and optimal dosing of GCs in DIILD.
The TRISTAN Consortium will address this research agenda and will focus on prospective studies
using novel imaging methods and biomarkers, with accompanying pre-clinical studies to interrogate
mechanisms and validate imaging methods. Our aim is to develop better biomarkers for use, both
in drug development and clinical practice, for the diagnosis and monitoring of DIILD and other ILD
subtypes. We also aim to undertake prospective work to estimate the burden of DIILD and take steps
towards developing a consensus on management.
Table 4. Key findings for each sub-question.
What is the incidence and prevalence of DIILD?
• Incidence rates estimated between 0.41 and 12.4 per million per annum
• DIILD accounts for 3–5% of prevalent cases of ILD
What drugs are commonly associated with DIILD?
• Cancer drugs followed by rheumatology drugs, amiodarone and antibiotics are the most common causes
of DIILD
• Risks are highest when causative agents are used in combination
• Some, but not all, drugs are associated with a dose-dependent risk of DIILD
• Presentations and outcomes can vary even with the same agent
What are the risk factors for developing DIILD?
• Smoking and pre-existing lung disease are significant risk factors for many agents
• Other risk factors for some, but not all, drugs are increasing patient age, drug dose, male gender, prior
therapy, high alcohol intake, presence of comorbid conditions and genetic susceptibility factors
Radiological investigation of DIILD and the prevalent radiopathological patterns
• Plain chest X-ray is often normal at presentation in DIILD
• CT is the imaging modality of choice in DIILD
• CT alone cannot discriminate between DIILD and other types of ILD
• Different radiopathological patterns of ILD can occur with the same causative agent
• No characteristic radiopathological findings are characteristic or pathognomic of DIILD, but OP, followed
by NSIP and HP, are the most frequently seen patterns
What is the role of non-imaging diagnostic investigations?
• Lung biopsy is not routinely indicated for investigation of DIILD
• BAL is an important investigation for the exclusion of infection
• There are currently no validated circulating biomarkers for the diagnosis or prognosis of DIILD
What is the impact of glucocorticoid (GC) therapy on DIILD outcome?
• There are no robust or comparative studies evaluating the adjunctive role of GC therapy alongside
withdrawal of the causative drug
• There is low-quality evidence to support the efficacy and dosing of corticosteroids by grade of severity
and radiopathological subtype of DIILD
• A pragmatic approach to use of GC is warranted, but further prospective studies are required to
investigate further
What if any factors predict prognosis?
• Prognosis is highly variable between agents and patient populations
• DAD pattern of DIILD is associated with high mortality, but CT pattern alone is not consistently found to
be a predictor of mortality
• Severity at presentation and acute onset are the most consistent predictors of mortality
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